Black Rock Inc. Next Cure, Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Next Cure, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 761,334 shares of NXTC stock, worth $1.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

761,334

Previous 890,102 14.47%

Holding current value

$1.17 Million

Previous $1.01 Million 67.36%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$1.13 - $2.23 $145,507 - $287,152	-128,768 Reduced 14.47%	761,334 $1.7 Million
Q4 2023 Feb 13, 2024	SELL	$1.03 - $1.45 $8,244 - $11,605	-8,004 Reduced 0.89%	890,102 $1.01 Million
Q3 2023 Nov 13, 2023	SELL	$1.29 - $1.84 $35,106 - $50,073	-27,214 Reduced 2.94%	898,106 $1.16 Million
Q2 2023 Aug 11, 2023	BUY	$1.47 - $1.86 $1,318 - $1,668	897 Added 0.1%	925,320 $1.67 Million
Q1 2023 May 12, 2023	SELL	$1.46 - $1.83 $178,620 - $223,887	-122,343 Reduced 11.69%	924,423 $1.37 Million

Q4 2022 Feb 13, 2023	SELL	$1.2 - $2.49 $240,121 - $498,251	-200,101 Reduced 16.05%	1,046,766 $1.48 Million
Q3 2022 Nov 14, 2022	SELL	$2.97 - $5.19 $52,488 - $91,722	-17,673 Reduced 1.4%	1,246,867 $3.43 Million
Q2 2022 Aug 12, 2022	SELL	$3.38 - $5.27 $5,320 - $8,294	-1,574 Reduced 0.12%	1,264,540 $5.94 Million
Q1 2022 May 12, 2022	BUY	$4.76 - $6.24 $114,149 - $149,641	23,981 Added 1.93%	1,266,114 $6.15 Million
Q4 2021 Feb 10, 2022	BUY	$5.7 - $9.1 $69,152 - $110,401	12,132 Added 0.99%	1,242,133 $7.45 Million
Q3 2021 Nov 09, 2021	BUY	$6.74 - $8.02 $170,602 - $203,002	25,312 Added 2.1%	1,230,001 $8.29 Million
Q2 2021 Aug 11, 2021	BUY	$7.6 - $10.28 $9.16 Million - $12.4 Million	1,204,689 New	1,204,689 $9.68 Million

Others Institutions Holding NXTC

# of Institutions

Shares Held

16.1M

Call Options Held

10.5K

Put Options Held

View Full List

About NextCure, Inc.

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $42.7M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

More about NXTC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account